Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 12;15(1):69.
doi: 10.1186/s13023-020-1332-x.

A roadmap to using historical controls in clinical trials - by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)

Mercedeh Ghadessi  1 , Rui Tang  2 , Joey Zhou  3 , Rong Liu  4 , Chenkun Wang  5 , Kiichiro Toyoizumi  6 , Chaoqun Mei  7 , Lixia Zhang  8 , C Q Deng  9 , Robert A Beckman  10
Affiliations
Review

A roadmap to using historical controls in clinical trials - by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)

Mercedeh Ghadessi et al. Orphanet J Rare Dis. .

Abstract

Historical controls (HCs) can be used for model parameter estimation at the study design phase, adaptation within a study, or supplementation or replacement of a control arm. Currently on the latter, there is no practical roadmap from design to analysis of a clinical trial to address selection and inclusion of HCs, while maintaining scientific validity. This paper provides a comprehensive roadmap for planning, conducting, analyzing and reporting of studies using HCs, mainly when a randomized clinical trial is not possible. We review recent applications of HC in clinical trials, in which either predominantly a large treatment effect overcame concerns about bias, or the trial targeted a life-threatening disease with no treatment options. In contrast, we address how the evidentiary standard of a trial can be strengthened with optimized study designs and analysis strategies, emphasizing rare and pediatric indications. We highlight the importance of simulation and sensitivity analyses for estimating the range of uncertainties in the estimation of treatment effect when traditional randomization is not possible. Overall, the paper provides a roadmap for using HCs.

Keywords: Clinical trial; Historical control; Pediatric indication; Rare disease; Real world data; Real world evidence; Sensitivity analysis; Simulation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Decision Making Diagram for using HCs in Clinical Trials
Fig. 2
Fig. 2
Clinical Trial using HCs Simulation Process
Fig. 3
Fig. 3
Visualization of Comparison of the “Sweet Spots” of Methods via Simulation
Fig. 4
Fig. 4
Existing Registry – Historical Assessment
Fig. 5
Fig. 5
Existing Registry – Suitability Assessment
See this image and copyright information in PMC

References

    1. Eichler HG, Bloechl-Daum B, Bauer P, Bretz F, Brown J, Hampson LV, et al. “Threshold-crossing”: a useful way to establish the counterfactual in clinical trials? Clin Pharmacol Ther. 2016;100(6):699–712. doi: 10.1002/cpt.515. - DOI - PMC - PubMed
    1. Beckman RA, Clark J, Chen C. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nat Rev Drug Discov [Internet]. 2011[cited 2018 may 2];10(10):735–748. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21959287. Accessed 2 May 2018. - PubMed
    1. Thomas N. Historical Control. 2008 [cited 2018 Apr 9];1–3. Available from: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9780471462422.eoct347.
    1. Hill AB. THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION? Proc R Soc Med [Internet]. 1965 May;58:295–300. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2626428/. Accessed 9 Apr 2018. - PMC - PubMed
    1. Byar DP, Schoenfeld DA, Green SB, Amato DA, Davis R, De Gruttola V, et al. Design considerations for AIDS trials. N Engl J Med [Internet] 1990;323(19):1343–1348. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199011083231912. - PubMed

Substances